Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2023-06-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司关于2022年年度报告的更正公告
Regulatory Filings Classification · 95% confidence The document is titled as a correction announcement regarding the 2022 Annual Report of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It specifically states that the original 2022 Annual Report disclosed on April 27, 2023, contained errors which are now being corrected. The content focuses on environmental and social responsibility disclosures, correcting previous environmental data and compliance information. The document is an announcement correcting parts of the annual report rather than the full annual report itself. The length is 6926 characters, which is relatively short and consistent with a correction or announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a correction announcement related to the annual report, not the full annual report itself.
2023-06-02 Chinese
江苏四环生物股份有限公司关于对深圳证券交易所2022年年报问询函回复的公告
Annual Report Classification · 95% confidence The document is a detailed response from Jiangsu Sihuan Bio Co., Ltd. to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2022 annual report. It contains extensive financial data, analysis of revenue, profit, cash flow, business segments, product sales, cost and margin analysis, risk assessment, and future business plans for 2023. The document includes auditor opinions and detailed explanations of financial results and operational conditions for the fiscal year 2022. The presence of comprehensive financial statements, management discussion, and auditor commentary indicates this is part of the annual report or a detailed supplement to it. Since the document is lengthy (15,000 characters) and contains substantive financial data and analysis rather than just an announcement or certification, it should be classified as an Annual Report (10-K). FY 2022
2023-05-23 Chinese
中审亚太会计师事务所关于江苏四环生物股份有限公司2022年年报问询函的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from an audit firm (China Audit Asia Pacific Certified Public Accountants LLP) to an inquiry letter from the Shenzhen Stock Exchange regarding the 2022 annual report of Jiangsu Sihuan Bioengineering Co., Ltd. It contains extensive financial data, analysis of revenue, profit, cash flow, cost structure, and explanations of business risks and accounting policies. The document includes auditor opinions on the financial statements and operational risks, detailed tables of financial figures, and management responses to specific questions about the annual report. The presence of audit procedures, financial statement analysis, and auditor opinions related to the 2022 fiscal year annual report clearly indicates this is an Audit Report / Information document rather than the full Annual Report itself or a simple announcement. The document length (15,000 characters) and detailed content confirm it is not a brief announcement or certification but a substantive audit report. Therefore, the correct classification is AR (Audit Report / Information). FY 2022
2023-05-23 Chinese
江苏四环生物股份有限公司关于监事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement regarding the re-election of the supervisory board (监事会) of Jiangsu Sihuan Bio Co., Ltd. It includes information about the composition of the new supervisory board, the nomination process, qualifications for candidates, and procedural details for the election. There is no financial data, no mention of financial results, no audit information, and no reference to any report publication. The document is clearly about management/board information, specifically about changes in the supervisory board members. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is under 5,000 characters, but it is not a mere announcement of a report publication; it contains substantive information about board changes.
2023-05-23 Chinese
江苏四环生物股份有限公司关于董事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement regarding the nomination and election process for the company's board of directors, including the composition of the new board, nomination procedures, qualifications for directors, and related administrative details. It does not contain financial statements, audit information, or other financial report content. It specifically focuses on the board of directors' election and related governance matters. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-05-23 Chinese
四环生物2022年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Jiangsu Sihuan Pharmaceutical Co., Ltd. It discusses the legality and validity of the AGM's convening, voting procedures, attendance, and resolutions passed. The document does not contain financial statements or detailed financial performance data but focuses on the legal compliance and procedural aspects of the AGM. It is not the AGM materials themselves but a legal opinion related to the AGM. Given the content and nature, the document best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the validation and legality of the AGM proceedings and voting results.
2023-05-17 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.